Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose and Food-effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics of AMG 378 in Healthy Participants.’ The study aims to assess the safety and tolerability of AMG 378, a new drug, in healthy volunteers. This research is significant as it lays the groundwork for future studies that could lead to new therapeutic options.
The intervention being tested is AMG 378, an oral tablet, which is being compared to a placebo. The study involves single and multiple ascending doses, as well as a food-effect cohort to understand how food intake affects the drug’s absorption and efficacy.
The study design is interventional, with a randomized and sequential intervention model. It includes a double-blind masking approach, meaning both participants and investigators are unaware of who receives the drug or placebo. The primary purpose is to gather basic scientific data on AMG 378.
The study began on March 28, 2025, with the latest update submitted on June 6, 2025. These dates are crucial as they indicate the study’s progress and the timeliness of the data being collected.
For investors, this study could influence Amgen’s stock performance, as positive outcomes may boost investor confidence and market value. The pharmaceutical industry is highly competitive, and advancements in drug development can significantly impact market dynamics.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.